
ITV AND PTV MARGINS IN THE IGRT ERA

Joep Stroom



Champalimaud
Foundation

International Conference on Advances in Radiation Oncology (ICARO-2)



IAEA Vienna, June 21, 2017

Outline

- PTV margin recipes
 - Systematic and random uncertainties
- ITV
- Delineation uncertainties
- CTV margin recipe
- Combined margin recipe
- Summary / conclusions

PTV margin recipes (ICRU 50/62/83)

Table 4.4. Summary of various published recommendations for margins around target volumes (CTV) and OAR (modified from van Herk, 2004).

Author	Region	Recipe	Comments
Bel <i>et al.</i> (1996)	PTV	0.7σ	Statistical uncertainties only (linear approximation)—Monte Carlo.
Antolak and Rosen (1999)	PTV	1.65σ	Statistical uncertainties only, block margin?
Stroom <i>et al.</i> (1999a)	PTV	$2\Sigma + 0.7\sigma$	95 % absorbed dose to on average 99 % of CTV tested in realistic plans.
van Herk <i>et al.</i> (2000)	PTV	$2.5\Sigma + 0.7\sigma$ (or more correctly): $2.5\Sigma + 1.64(\sigma - \sigma_e)$	Minimum absorbed dose to CTV is 95 % for 90% of patients. Analytical solution for perfect conformation.
McKenzie (2000)	PTV	$2.5\Sigma + \beta + (\sigma - \sigma_e)$	Extension of van Herk <i>et al.</i> (2000) for fringe dose due to limited number of beams. The factor β depends on the beam organization.
Parker <i>et al.</i> (2002)	PTV	$\Sigma + \sqrt{(\sigma^2 + \Sigma^2)}$	95 % minimum absorbed dose and 100 % absorbed dose for 95 % of volume. Probability levels not specified.
van Herk <i>et al.</i> (2002)	PTV	$2.5 + \Sigma + 0.7\sigma + 3 \text{ mm}$ (or more correctly): $\sqrt{2.7^2\Sigma^2 + 1.6^2\sigma^2} - 2.8 \text{ mm}$	Monte Carlo based test of 1 % TCP loss due to geometrical errors for prostate patients, fitted for various σ and Σ .

Symbols: Σ , standard deviation of systematic uncertainties; σ , standard deviation of statistical (random) uncertainties; σ_e , describes width of beam penumbra fitted with a Gaussian function; A , peak-to-peak amplitude of respiration.

Patient group characterization by Σ and σ

mean of means

$$M: \langle m_i \rangle \approx 0$$


systematic deviation

$$\Sigma : \text{sd}(m_i)$$

random deviation

$$\sigma : \langle \text{sd}_i \rangle$$

Group of 4 patients




Two types of uncertainties

Systematic	Random
Mean difference with the planning (i.e. same for all fractions)	Day-to-day (multi-fraction) difference with the planning situation
Characterized by Σ : the standard deviation of the mean differences per patient in the group	Characterized by σ : the mean of the standard deviation per patient
Examples: delineation uncertainties, organ motion, setup error	Examples: organ motion, setup error, breathing
Total systematic uncertainty by quadratic addition of components	Total random uncertainty by quadratic addition of components
Dosimetric effect: shift	Dosimetric effect: blurring


NB: also valid in the IGRT era!

Effect of σ on dose distribution

- Random errors vary from fraction to fraction
 - Or within fraction
- Effect on final dose:
 - Smoothing or blurring of the dose
 - Low dose regions grow
 - High dose regions shrink
 - MARGIN



Mean DVHs for “moving” CTVs



Use these curves to determine margin recipe (1999):

1. criterion: $D_{99_{<CTV>}} > 95\%$ (somewhat arbitrary!)
2. recipe: $M(\Sigma, \sigma) = 2\Sigma + 0.7\sigma$


Margin recipes allowing $P_{\text{underD}} = 10\%$

Criterion:

- # patients with under-dose, $P_{\text{underD}} \leq 10\%$ (also arbitrary!)
- under-dose: $D_{\text{min}} < 95\%$

Geometric errors

e.g.: $\Sigma_{\text{geo}} = 3 \text{ mm}$, $\sigma_{\text{geo}} = 3 \text{ mm}$




Repeat for $N_{\text{pat}} = 1000$, all $(\Sigma_{\text{geo}}, \sigma_{\text{geo}})$

$$M_{\text{geo}} = a\Sigma_{\text{geo}} + b\sigma_{\text{geo}}$$


We found: $M_{\text{geo}} = 2.1\Sigma_{\text{geo}} + 0.8\sigma_{\text{geo}}$

Margins and Conformity Index (CI)

5 equi-angular beams, CI = 1.25



Ideal dose, CI = 1.0



$$M_{\text{geo}} = \mathbf{a} \Sigma_{\text{geo}} + \mathbf{b} \sigma_{\text{geo}}$$

5-field conformal				ideal dose			
a	SD(a)	b	SD(b)	a	SD(a)	b	SD(b)
2.1	0.1	0.8	0.2	2.5	0.0	0.9	0.2

Stroom 1999/2014

Van Herk 2000

PTV: quadratic addition of uncertainties

- $M = 2.1\Sigma + 0.8\sigma$
 - $\Sigma = \sqrt{(\Sigma_{\text{delineation}}^2 + \Sigma_{\text{setup}}^2 + \Sigma_{\text{organmotion}}^2 + \dots)}$
 - $\sigma = \sqrt{(\sigma_{\text{setup}}^2 + \sigma_{\text{organmotion}}^2 + \dots)}$
- Example:
 - $\Sigma_{\text{setup}} = 0$, $\Sigma_{\text{organmotion}} = 3 \rightarrow M = 6.3$
 - $\Sigma_{\text{setup}} = 3$, $\Sigma_{\text{organmotion}} = 0 \rightarrow M = 6.3$
 - $\Sigma_{\text{setup}} = 3$, $\Sigma_{\text{organmotion}} = 3 \rightarrow M = 8.9 < 12.6$

Margin calculation procedure


- determine all geometrical errors
 - own data or from literature
- determine overall Σ and σ
 - $\Sigma = \sqrt{(\Sigma_{su}^2 + \Sigma_{om}^2 + \Sigma_{del}^2)}$, $\sigma = \sqrt{(\sigma_{su}^2 + \sigma_{om}^2)}$
- apply margin rule: $M = 2\Sigma + 0.7\sigma$ (1999):

site	type	Σ x	Σ y	Σ z	σ x	σ y	σ z
prostate	Setup	1.2	1.0	1.1	2.1	1.8	2.0
	Organ motion	0.5	2.5	2.7	0.6	2.8	2.5
	Delineation	2.5	2.5	2.5	-	-	-
	Total	2.8	3.7	3.8	2.2	3.3	3.2
	M (mm)	7	10	10			

NB: 10 mm was the clinically applied prostate safety margin before 1999!


Consequences of recipe: CTV outside PTV

Systematic: $M = 2 \Sigma$




$P(\text{CTV outside PTV}) = 25\%$

Random: $M = 0.7 \sigma$



$P(\text{CTV outside PTV}) = 90\%$


Spherically symmetric case



Breathing motions (ITV?)

- Systematic or random?
 - Mostly random!
 - Dose will be blurred
- Approximate amplitude (A) by standard deviation
 - $\sigma_{\text{breathing}} \approx A / 3$ *
 - $\sigma_{\text{tot}} = \sqrt{(\sigma_{\text{setup}}^2 + \sigma_{\text{organmotion}}^2 + \sigma_{\text{breathing}}^2 + \dots)}$

Separate ITV overestimates margins!




Delineation uncertainty of GTV




- Visible and/or palpable tumor
- Reduction by new imaging techniques
 - CT, MRI, PET
- Multi-observer studies
 - Pathology is the gold standard!
- $\Sigma_{\text{delineation}}$ should go in PTV margin!

Multi-observer study lung

Without PET



With PET



SD ($\Sigma_{\text{delineation}}$)
projected on the
median delineated
surface (**from dark
blue (SD < 0.1 cm)**
to **red (SD > 1.5 cm)**)

With PET less random errors, but... What is the truth?

Overview delineation uncertainties

Who	Year	Tumor Site	#cases	#doctors	Images	SD(mm)	Reference
Steenbakkers	2006	Lung	22	11	CT / CT+PET	10 / 4	IJROBP 64, p435
Petric	2013	Cervix	6	10	MRI	4	RadOnc 107, p6
Rasch	1999	Prostate	18	3	CT / MRI	3 / 3	IJROBP 43, p57
Van Mourik	2010	Breast (boost)	8	13	CT / CT + clips	7 / 5	RadOnc 94, p286
Rasch	2005	Head&Neck (nasoph.)	18	10	CT / CT+MRI	4 / 3	Semin Radiat Oncol 15:136
Nijkamp	2012	Rectum	8	11	CT+MRI / + guideline	10 / 6	RadOnc 102, p14

Weakest link in radiotherapy?



Ignoring delineation errors

- Frequently, delineation errors are ignored in margin calculations
- But, TCP is not too bad
- This means that either:
 - Too large margins for other factors are applied accidentally compensating for delineation errors
 - There is an overall mean error in delineating, i.e., all delineations are too large (“better safe than sorry”)
 - See e.g. Daisne et al, Radiology. 2004, p93-100
 - NTCP can be improved by proper margins
 - TCP can really be improved by proper margins

CTV (Clinical Target Volume)

- Microscopic disease:
 - By definition not directly visible
 - Microscope required to measure this
- Relatively few histopathology studies have been performed
 - Low # patients
 - Low sampling frequency


Distribution of Microscopic disease



Margin recipes allowing $P_{\text{underdose}} = 10\%$

Microscopic disease

e.g.: $N_{\text{pat}} = 1000$, $N_{\text{islet/pat}} = 5$, $\Sigma_{\text{micro}} = 6 \text{ mm}$



Repeat for all $(N_{\text{islet}}, \Sigma_{\text{micro}})$



$$M_{\text{micro}} = (d + e \log(N_i)) \times \Sigma_{\text{micro}}$$

5-field conformal			ideal dose		
d	e	SD (d,e)	d	e	SD (d,e)
1.4	0.8	0.2	1.7	0.8	0.0

Discussion CTV margins

- Assumed in simulations
 - Microscopic disease are islets
 - Radio-sensitivity of Islets equal to GTV
- Where are all the real microscopic islets ($\ll 1\text{mm}$)?
- CTV margin often ignored altogether
 - See discussion delineation errors
- Undersampling at pathology ignored

Review

Trends in Molecular Medicine January 2012, Vol. 18, No. 1



Feature Review


Cancer invasion and resistance: interconnected processes of disease progression and therapy failure

Stephanie Alexander^{1,2} and Peter Friedl^{1,2,3}

¹ Department of Dermatology and Rudolf Virchow Center, DFG Research Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany

² David H. Koch Center for Applied Research of Genitourinary Cancers, Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

³ Microscopical Imaging of the Cell, Department of Cell Biology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands



Combining PTV and CTV margins

- Geometric uncertainties:

- $M_{\text{geo}} = 2.1\Sigma_{\text{geo}} + 0.8\sigma_{\text{geo}}$

- Microscopic uncertainties:

- $M_{\text{micro}} = (1.4 + 0.8\log(N)) \times \Sigma_{\text{micro}}$

- M_{micro} is systematic in nature:

- Add quadratically with Σ_{geo} ?


→ $M_{\text{GTV-PTV}} = \sqrt{((2.1\Sigma_{\text{geo}})^2 + ((1.4 + 0.8\log(N_i))\Sigma_{\text{micro}})^2)} + 0.8\sigma_{\text{geo}}$

Verification of combined formula

1) $M_{\text{GTV-PTV}} = \sqrt{((2.1 \Sigma_{\text{geo}})^2 + ((1.4 + 0.8 \log(N_i)) \Sigma_{\text{micro}})^2) + 0.8 \sigma_{\text{geo}}}$

2) Simulate both geometric and microscopic uncertainties

e.g.: $N_{\text{pat}} = 1000$, $\Sigma_{\text{geo}} = 3 \text{ mm}$, $\sigma_{\text{geo}} = 3 \text{ mm}$, $N_{\text{islet/pat}} = 5$, $\Sigma_{\text{micro}} = 6 \text{ mm}$



Repeat some
(Σ_{geo} , σ_{geo} , N_{islet} , Σ_{micro})
for verification



Msimulation

GTV to PTV: verification for 54 cases

$\Sigma_{\text{geo}}=(2,4\text{mm})$, $\sigma_{\text{geo}}=(0,2,4\text{mm})$, $\Sigma_{\text{micro}}=(3,6,9\text{mm})$, $N_i=(3,15,75)$.

$M_{\text{simulation}} - M_{\text{recipe}}$ (mm)			
5-field conformal		ideal dose	
mean	SD	mean	SD
0.2	0.8	0.1	0.7

Comparison with linear ICRU approach (GTV, CTV, PTV)

$M_{\text{ICRU}} - M_{\text{new recipe}}$ (mm)			
5-field conformal		ideal dose	
mean	SD	mean	SD
4.5	1.4	5.4	1.6

Summary: over/underestimation PTV

- No clin. validation margin criteria: **OVER/UNDER**
- Assuming perfect dose conformance: **OVER**
- Using a separate ITV: **OVER**
- Ignoring error sources (e.g. delineation): **UNDER**
- “Better safe than sorry” delineations: **OVER**
- Separate CTV and PTV margins: **OVER**
- Ignore undersampling @pathology: **UNDER**
- Unknown radiosensitivity Σ_{micro} : **OVER/UNDER**

-
- **Total:** **0?**

Conclusions

- GTV and CTV delineation may be largest uncertainty in RT
- Margin factors are to some extent arbitrary
 - But systematic errors have more weight
 - ITV is wrong
- CTV and PTV margins should be combined
 - Otherwise margins overestimated by up to 5 mm
- Margins used in the clinic should be consistent and based on uncertainties

TCP-based GTV-PTV margins

- Similar simulations using criterion $\Delta\text{TCP}=1\%$:


$$M_{\text{GTV-PTV}} = \sqrt{\{(2.6\Sigma_{\text{geo}})^2 + ([1.7+0.7\log(N_i)]\Sigma_{\text{micro}})^2 + (1.8\sigma_{\text{geo}})^2\}} - 3.8\text{mm}$$

- TCP should be clinically more relevant
- However
 - TCP parameters add extra uncertainty
 - Much more sensitive to tumor size, prescription dose, etc
- Currently preferred: D_{min} -based recipes

Combined margin robustness

	Ref. value	Value range		Margin range (%)	
		min	max	Crit: D _{min}	Crit: TCP
Geometry					
penumbra width (SD, mm)	3.2	1	7	92-118	70-135
tumor diameter (cm)	3	1	10	-	74-107
microscopic islet radius (mm)	2	0.5	4	-	96-102
dose conformity Index	1.25	1	1.3	99-118	95-107
TCP parameters					
<TCP>	0.8	0.25	0.9	-	75-101
nfrac	40	25	50		
relative islet radiosensitivity (%)	100	75	150	-	87-109
Plan criteria					
minimal PTV dose (%)	95	95	95	102-112	95-112
PTV coverage (%)	100	90	100		
Margin criteria					
$P(D_{\min} < 95\%) < X\%$	10	1	25	85-137	-
$\Delta TCP < Y\%$	1	0.1	10	-	35-145

GTV validation: surgical specimens



1. Pharyngolaryngeal Squamous Cell Carcinoma: CT, MRI, PET, Surgical specimen
2. **All imaging volumes are too large, PET closest to surgery**
3. Microscopic disease invisible with imaging
4. Daisne et al, Radiology. 2004, p93-100.